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The aim of this review is to place a historical perspective on linking dyslipidaemia with
atherosclerosis and emphasises previous knowledge about the impact on the lipoprotein profile
and health in persons with mild dyslipidaemia and in those with defined genetic disorders.
CVD is becoming the leading cause of death and disability in developed and developing
countries and is strongly related to lifestyle factors that influence plasma lipoprotein con-
centrations. It is established that risk of complications from atherosclerosis increases with
increasing LDL and decreasing HDL and that there is potentiation of risk when these and
other risk factors co-exist. High-fat diets used for losing body mass may increase risk through
dyslipidaemia. Pharmaceutical modulation of the lipoproteins has lowered risk powerfully but
residual risk persists, possibly relating to existing disease as well as progression relating in
many instances to dietary lipids. The impact of various dietary lipids is reviewed as they relate
to the conventional lipoprotein profile in persons who do not have significant metabolic defects,
as well as the impact on inherited metabolic disease such as familial hypercholesterolaemia,
hypertriglyceridaemia and phytosterolaemia. For most persons with dyslipidaemias a sig-
nificant benefit will be seen on the lipid profile by adopting a low saturated fat diet with less
cholesterol intake.
Dietary lipid: Dyslipidaemia
Recommendations about the amounts and kinds of
dietary fat to achieve good health without altering the risk
of cardiovascular complications have been derived from
many studies over many years. Epidemiologic studies
typically reflect the general trends relating to lifestyle in
which the diet is a major factor but over long periods of
time. In contrast, short-term, well-designed interventional
studies with appropriate controls can define changes relat-
ing to specific interventions on blood plasma lipoproteins,
which have proven influences on the risk of CVD. Recent
dietary fashions for body mass reduction and improved
health have appealed to the public. A high-fat, high-protein
diet has gained popularity for short-term mass loss(1) even
though the public is aware that the increased cholesterol
and saturated fat intake are generally accepted to have
adverse effects. This document will briefly review the
insights over the past three decades that relate the impact
of dietary lipids on lipoprotein metabolism as it applies
to the person with mild dyslipidaemia and those persons
who have inherited metabolic disorders in lipoprotein
metabolism.
Dyslipidaemia
Dyslipidaemia may be defined as any change of lipids or
lipoproteins, quantitatively or qualitatively, in the blood
that signifies an increased risk of disease. The lipid profile,
whether in a state of health or disease, is the result of
interplay between genes and the environment with varying
contributions in each individual. Nutrition is a powerful
connection between these two processes. Important nutri-
tional considerations include energy consumption, macro-
nutrients and micro-nutrients as well as interaction
between these nutrients and genes, over variable periods of
time and with different requirements at physiologic or
pathologic changes.
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Vascular disease is generally multi-factorial and rela-
tively low in the population at large until an elderly state is
reached although lifestyle-related factors may increase
risk. The risk is very high and practically unifactorial in
individuals with severe metabolic errors such as familial
hypercholesterolaemia in which the average age of death
from myocardial infarction was at the age of 43 years for
men(2). The monogenic disorders bringing about athero-
sclerosis are usually easy to identify in a family: severe
hypercholesterolaemia is a clear indicator of an adverse
outcome, but the polygenic disorders are less predictable
and may be further compounded by modulating genes and
lifestyles.
The chief concern about dyslipidaemia is athero-
sclerosis. The pathophysiology has been studied inten-
sively since the response to injury hypothesis(3). It is an
inflammatory process that is modifiable. Epidemiologic
studies reveal that lifestyle factors including diet, obesity
and certain common disorders such as hypertension,
diabetes and chronic kidney disease play significant roles
and (partially) successful intervention with pharmaceutical
agents culminated in clinical guidelines for persons at risk,
such as recently published in South Africa(4).
The pathophysiology of atherosclerosis is one of gradual
progression. The process commences with endothelial
damage and the penetration of lipoproteins and leucocytes
finally lead to plaque formation where rupture and throm-
bosis can suddenly cause complications(5). To combat the
complications of dyslipidaemia it is desirable that the risk
be identified early, and that intervention addresses all risk
factors and not only the predominant one. The evidence-
base for medication to reduce the risk of complications(6)
is better than that for nutritional interventions although it
appears that a low-fat diet has cardiovascular benefits
exceeding the degree of blood cholesterol reduction(7).
It should be borne in mind that there is a postprandial ex-
posure to chylomicrons and remnants that may affect
vascular function, including effects attributable to ther-
mally stressed lipid(8). However, in the fasted state, it is
mainly the lipoproteins from the liver that are observed
and of particular interest is LDL on which guidelines,
including the South African guidelines, focus. Depending
on the contextual risk of the patient, the treatment target
for LDL cholesterol is <3mM/l, <2.5mM/l and <1.8mM/l
in the usual, high risk and very high risk settings, respec-
tively(4). It is noted that a change of LDL cholesterol by
1mM/l lowers the cardiovascular events by 22 %.(6) It has
become clear that hyperlipidaemias where the TAG is
higher than the ideal (1.7mM/l) and low HDL cholesterol
also confer risk and may be targets for intervention as well.
The prediction of CVD in people who do not have
identifiable monogenic disorders is difficult. Epidemiologic
evidence from the seven countries’ study(9) indicated
a relationship between the cardiovascular mortality and
the plasma cholesterol concentration. Within a population
there appears to be an exponential rise in risk in the range
seen in a developed country(10). Risk prediction can further
be refined by sub-dividing cholesterol to HDL cholesterol
and LDL cholesterol(11) but postprandial phenomena and
the nature of fatty acids are less amenable to analysis
and study.
Impact of dietary fats on the plasma lipid profile
In people with mild dyslipidaemia there can be significant
differences in TAG excursion after a meal. Longer post-
prandial TAG exposure in people with the atherogenic
lipoprotein phenotype(12) comprising modest hyper-
triglyceridaemia, mildly depressed HDL cholesterol con-
centration and small dense LDL may not be recognised by
conventional tests. Several biological determinants have
been found for the atherogenic lipoprotein phenotype: it
is more common in males and with increasing age, and is
strongly influenced by BMI or waist :hip ratio. During
pregnancy this change happens physiologically as a result
of increasing TAG concentration. The atherogenic lipo-
protein phenotype may also display a familial trait. Even
though high carbohydrate diets may increase VLDL con-
centration somewhat and fail to raise HDL, the lesser
postprandial exposure to remnants of TAG-rich post-
prandial lipoproteins may confer benefit in the atherogenic
lipoprotein phenotype as well.
The response to ingested cholesterol is also known to
be variable and to be saturable. Considering the amount of
cholesterol in food, the plasma volume and the rapid
clearance from the circulation, the effect of a cholesterol-
rich feed on plasma cholesterol is negligible when viewed
over hours to a day. However, with sustained cholesterol
feeding the modulation of the LDL receptor reduces
hepatic uptake of plasma LDL and plasma LDLC rises
with a mean of about 1.5mM/l(13) to achieve a new steady
state between production and clearance of LDL. There are
normal subjects who have different steady states with
normal variants in apoE(14) and apoAiv(15).
The nature of the dietary fatty acids also influences the
response. Saturated fatty acids promote the LDL elevation
and PUFA reduce the LDL increase on cholesterol feed-
ing(16). Cholesterol feeding increases LDL and usually
also HDL cholesterol, saturated fats in the diet also tend
to increase LDL and HDL. MUFA may decrease LDL
somewhat, leaving HDL cholesterol normal. PUFA, some
of which are essential, tend to decrease HDL and LDL
cholesterol. The n-3 PUFA may, especially with mild
hypertriglyceridaemia, increase the LDL cholesterol(17).
Trans-unsaturated fatty acids are known to decrease HDL
cholesterol, whereas SFA increase LDL cholesterol(18).
Table 1 summarises information on lipoprotein responses
to cholesterol and different classes of fatty acids, bearing in
mind that dietary manipulation may not only increase one
entity but could also decrease another.
Although the effects of dietary lipids on lipoproteins
may be relatively small in most people, they can certainly
have significant impact in a lifetime and may also influ-
ence other processes that govern outcome. The role of n-3
PUFA in inflammation as well as the healing response has
recently been recognised(19). There are also epidemiologic
studies that indicate reductions in heart disease with
increases in consumption of n-3 fatty acids as fish(20) or
supplementations(21). An n-3 index has been suggested(22)
by relating the sum of EPA and DHA to the sum of all the
fatty acids in red cell membrane. If <4 %, then supple-
mentation of 1–3 g n-3 PUFA/d is recommended. If >8 %,
it is viewed as desirable and no action needs to be taken.
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Between 4 and 8 % requires 0.5–1 g/d n-3 PUFA supple-
mentation. The benefit f such an approach has not been
verified in an interventional study but additional intake of
n-3 fatty acids over a diet containing several portions per
week may be worthwhile in very high risk cases.
Another dietary component that may modulate the
plasma cholesterol concentration is the consumption of
plant sterols and stanols. Plant sterols have about 3 %
uptake and plant stanols (saturated B-ring) have an uptake
of about 0.3 %. These molecules displace cholesterol from
the micelle in the gut and impair uptake of cholesterol
into the enterocyte at the level of Niemann–Pick C1-like
protein 1. Once taken in the plant sterols are preferentially
secreted by adenosine binding cassette G5 and G8 into
the intestinal or biliary tract(23). Lessening the absorption
of the cholesterol in the intestinal lumen reduces the
delivery of cholesterol to the liver and consequently there
is an up-regulation of LDL receptors that within 4 weeks
will lower the LDL cholesterol by approximately 9 %. The
finding(24) that higher plant sterol concentrations predict
vascular disease may refer more to higher sterol absorption
than an adverse effect as a recent review did not find the
consumption or plasma concentration of plant sterols to be
predictive of vascular disease(25). While recognising that
no outcome studies are available on the use of plant sterols
their use is nevertheless recommended(26). Importantly,
plant sterols are contra-indicated in patients with phytos-
terolaemia, a rare disease that is recessively inherited and
masquerades clinically similar to familial hypercholes-
terolaemia.
Hypertriglyceridaemia and other dyslipidaemias
The management of dyslipidaemia focuses mainly on
atherosclerosis but hypertriglyceridaemia is important to
treat as there is a high risk of pancreatitis as well, with
significant morbidity and mortality. Most of the fatty acids
in the diet are in TAG but phospholipids and, to a very
limited extent, cholesterol ester also contributes to fatty
acid intake. Fatty acids are re-assembled into TAG in the
enterocyte and are transported in chylomicrons. It is not
generally appreciated that the plant oils are pure TAG
which lend taste, texture and satiety to food but may be
harmful if consumed in large amounts in cases of hyper-
triglyceridaemia. The dietary variation in TAG intake is
large: 20–200 g/d. If a bolus of fat of 85 g (approximately
100mM) is consumed, with complete absorption and dis-
tribution into 3 litres plasma, the change in plasma
concentration will be 33mM/l if no clearance occurs. This
is the case in familial chylomicronaemia of which lipo-
protein lipase deficiency is the commonest cause. Inherited
as a recessive condition this may be unexpected in a family
and the diagnosis may be delayed. The lipaemic blood will
be evident in the neonatal period and eruptive xanthomata
will usually precede the onset of pancreatitis. Recurrent
pancreatitis will cause failure to thrive and can bring
about exocrine and endocrine failure of the pancreas. The
response to the low-fat diet is dramatic. For an adult,
restricting the intake of TAG to 25 g daily will usually
avoid recurrent pancreatitis. Infants and children need
special dietary assistance to ensure optimal energy supply
as well as complete nutrition.
Rare but severe disorders such as phytosterolaemia
and adrenoleukodystrophy require very special dietary
lipid modifications. Phytosterolaemia may cause severe
hypercholesterolaemia that could be mistaken for familial
hypercholesterolaemia except that it is recessively inher-
ited. Adrenoleukodystrophy is an X-linked recessive dis-
order in which very long-chain fatty acids accumulate but
do not alter the conventional measurements of plasma
lipoproteins. The diagnosis and management of these dis-
orders are best undertaken at specialised lipid clinics.
Conclusion
Atherosclerosis is generally multifactorial and is sig-
nificantly influenced by lifestyle in which diet is important
from the point of view of energy as well as other macro-
nutrient intakes. The nature of fatty acids, even while
appearing to have a low impact on lipoprotein concentra-
tions, may play a role in the pathophysiology of athero-
sclerosis through other mechanisms. These mechanisms
include postprandial vascular exposure and reactivity,
coagulation and inflammation. The human individual
has not evolved for avoidance of atherosclerosis but with
current expectations of longevity it is important to ensure
good nutrition that will avoid, or at least minimise,
atherosclerosis and its complications.
How does the information gathered about diet and
dyslipidaemia translated into practice for the person with
mild dyslipidaemia? The ideal diet has the appropriate
energy intake to sustain a lean body. Attempts to lose
weight by low carbohydrate diets with increased protein
intake, and usually also increased saturated fat intake may
increase the risk of vascular disease(27). The intake of TAG
Table 1. Collation of plasma lipoprotein responses to various
dietary lipid changes
Lipid TAG TC HDLC LDLC
Cholesterol* N I (I) I
SFA† (I) I (I) I
MUFA‡ (D) D N D
PUFA§ (D) D (D) D
n-3 PUFA{ D (D) (D) (I)
t-UFAk N I D (I)
MCTAG** D N (D) (N)
TC, total cholesterol; HDLC. HDL cholesterol; LDLC, LDL cholesterol;
t-UFA, trans unsaturated fatty acids; MCTAG, medium-chain TAG.
D, decrease; I, increase; N, neutral; () variable responses.
*Response to cholesterol feeding is increased by SFA and decreased
by PUFA.
†SFA promote coagulation and inflammation.
‡MUFA have low oxidation potential.
§PUFA from plants provide essential fatty acids, mostly of n-6 type,
but some a-linolenic acid is a C18 n-3 PUFA.
{n-3 PUFA delay coagulation and enhance repair after inflammation.
kt-UFA occurs at low concentration in products from ruminants and at higher
concentrations in partially hydrogenated PUFA.
**MCTAG release fatty acids that proceed to the liver through the portal vein
and are more readily taken into mitochondria for oxidation, useful in
management of hypertriglyceridaemia.
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is important for essential fatty acids and ensuring adequate
nutrition for other nutrients will, except in the vegan, result
in some cholesterol intake. In specific metabolic conditions
very restricted diets may be required to ameliorate the
disorder, mostly together with medication. The healthy diet
in general comprises cereals, vegetables, fruit, legumes
and nuts with marine products as a source of protein, while
poultry and occasional red meat will not be problematic.
Dairy products should preferably be low in fat unless
consumed in small amounts. Nutriceuticals that may be
of value are n-3 fatty acids and phytosterol spreads. The
usual westernised profile of LDL hypercholesterolaemia
can be viewed to be in a continuum with more severe
LDL hypercholesterolaemias. Thus, the success of an
intensively counselled ‘portfolio’ diet on plasma bio-
chemical parameters(28) in the setting of hyperlipidaemia
could be translated to less severe dyslipidaemias in persons
at risk for vascular disease, by advocating the use of plant
sterols, soya protein, viscous fibres and nuts.
While this approach will have a dramatic impact on
population statistics, patients with monogenic disorders
need more accurate diagnosis and more aggressive treat-
ments. Such problems are best evaluated at special centres
such as lipid clinics. Uncommon and rare disorders such as
hypertiglyceridaemia and phytosterolaemia, respectively,
should be accompanied by much specialised dietary man-
agement. In the future, it is hoped that research in nutrition
and disease will be able to identify more subtle patterns
relating to the lipid profile, including fatty acid profiles
and possibly provocative tests and interactions with genes,
so that dietary advice can be tailored for all individuals.
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